News information
Biomobie Technology
“Leading CEO’s Dialogue” | With the logic of “Many a little make a mickle,” achieve a new breakthrough in management of chronic disease

(From Outpatient magazine, if involved in infringement, please contact us promptly)

According to the report of the state of nutrition and chronic diseases in China (2015), the prevalence and rising rates of chronic diseases among younger people in China is the main cause affecting the health and mortality of the population. Thus, the prevention and control of chronic diseases is imperative. Although our country has taken some measures to prevent and control chronic disease occurrence and development, there are still some problems such as low awareness rate, low medication rate, and low control rate. So there must be a shift in focus to achieve higher awareness, treatment and control rates. In view of this, Outpatient magazine specially invited Peking University People's Hospital professor Hu Dayi and Biomobie (Shanghai) Regenerative Medicine Technology Co., Ltd. CEO Jack Wang to talk about how to achieve a new breakthrough in the management of Chinese chronic diseases from the perspective of cardiovascular prevention and rehabilitation in China.

 

On-the-spot interview

INTERVIEW

 

 

Outpatient magazine

“Nutrition and chronic diseases among residents in China (2015)” and “2015 China enterprise employees health and medical benefit” both report that chronic disease has become the major influential factor in Chinese residents' health. Please talk about the significance of chronic disease prevention and control on population health management and the strategy of chronic disease management in China.

 

Professor Hu

 

Chronic disease has become the world's deadliest disease, but with the development of China's economic and social change, rapid urbanization and aging, coronary heart disease, hypertension, diabetes, stroke and other chronic diseases involving heart and head blood-vessels have replaced infectious diseases as the most pressing health problem facing residents in China. Chronic disease is the leading cause of death in our country and the main challenge for the health sector. At present, the mortality rate of chronic diseases in China accounts for more than 85 percent of the total mortality rate, i.e., at least four deaths per five people. Chronic diseases consume vast health care resources.

 

Beijing, Shanghai and Hangzhou are three cities in China with a resident life expectancy of more than 80 years, but the healthy life expectancy is only 60 years. The next 20 years are spent trying to survive chronic diseases. The pain as well as the burden to the family and society makes this a serious situation. The actual treatment following diseases contributes only 8% to the healthy life. Although in China we strive to establish more large hospitals, to develop more experts in the medical disciplines, to expand more outpatient services, and to increase the amount of surgery, we too often ignore the real contribution to health and longevity, which is personal lifestyle and behaviors.

 

Two things must be done to achieve "healthy China." First, the Party and government need to assume the responsibility for people's health and integrate health into all policies. The government has led the way in building a healthy social environment, such as smoke-free public places, prioritizing the health of the people utilizing strategic development, but without universal health, there is no prosperity for all. The second is to wage a people's war, that is, mobilize the population. Like the special emphasis placed by the leaders of the country, "joint prevention and control, mass prevention and control, joint construction and sharing" have deeply integrated the fitness for all and the health of the whole people, making each individual responsible for his and her own health and learning self-health management. Only by proactively changing unhealthy lifestyles and behaviors can there be hope for health.

 

 

 

Outpatient magazine

According to over 40 years of research at home and abroad, many chronic diseases are accompanied by varying degrees of systemic or local, acute or chronic microcirculation disorders. Improving microcirculatory disorder becomes a new target for chronic disease. Can you talk about the impact of microcirculatory disorders on diseases and how to apply new techniques to improve microcirculation to manage chronic disease?

 

Professor Hu

 

On chronic disease management, at the macro level, it is necessary to rely on the government's macro policy support and the self-management of the people. At the micro level, it is necessary to carry out such things as people can understand, remember, use, and do, such as adhering to exercise. Second is the most closely watched intestinal flora problem (the intestinal flora disorder is associated with many chronic diseases). Third, microcirculation, namely regenerative medicine. Nowadays, western modern medicine and traditional medicine have placed too much emphasis on disease intervention (such as stent implantation for vascular stenosis), neglecting the immunity, compensatory and regenerative ability of mobilizing the body's own defense against diseases. For coronary heart disease, for example, it is exercising in order to stimulate collateral circulation thus stabilizing coronary heart disease. In fact, so far, there is no evidence that stents can reduce the overall mortality of stable coronary heart disease, but use of drugs and aerobic exercise does promote the body's own compensatory regeneration.

 

Exercise, intestinal flora, and microcirculation are well known, but managing chronic conditions requires close attention to staying active, developing specific, effective and actionable intervention tools that are understandable and remembered. These methods have to be lived, seen, and touched so that they can be trusted by the population, such as walking 10,000 steps daily to reduce body weight by 20 kg. For the use of vascular regeneration technology to improve microcirculation and promote the regeneration of capillaries, people need to actually see the original clumping together of erythrocytes, observe their blood flow speed, reduction of the blood composition of the floc, and capillary numbers. When the people see real results, they will trust the intervention.

 

 

 

Outpatient magazine

According to the relevant medical information, the human body's ability to repair itself is divided into two types: spontaneous healing and repair, and another is the need for certain elements to activate the repair function from the latent state. The new technology of R7 will make the wish come true. What is the technology of R7? How does it stimulate cell repair and regeneration? Where does it come from?

 

Jack Wang

 

R7 is a non-interventional physical therapy combined with electromagnetic technology and traditional medicine, developed by U.S. Silicon Valley Biomobie Corp., USA. In fact, the technology comes from the human body itself. In other words, it's a technology that was developed based on the human body's own repair mechanism. All living things on earth are created by the natural environment. Humans and animals share a common denominator in the field of regeneration, which means that basic injury repair takes on average seven days. The lizard tail can be regenerated in 7 days, and in the same way, the stitches in the body can usually be taken out in 7 days after surgery. R in English stands for regeneration, 7 represents 7 days, so the technique of regenerating blood vessels is called R7.

 

In fact, when the human and animal body are injured, the injury site sends out a distress signal, and when the signal is received, the body starts the repair process. So, if you want to know how the body can self-repair, we need to know what the key signals are; it is like the key that opens the right door. When we open that door the right direction to research is pointed out.

 

In practice, the frequency of the waveform signal needs to be obtained from the quantitative measurements, refined through tissue analysis to form a mathematical model, and the accuracy of the mathematical model then needs to be verified through cell experiments, animal experiments and double-blind clinical trials, with the results simulating the body's own regeneration repair signals. In other words, it simulates the human regenerative repair signal, through the pulse current, for the regeneration and repair of vascular walls and blood flow.

 

 

 

Outpatient magazine

So what is the background and evidence available supporting R7 technology?

 

Jack Wang

 

Professor Hu has described at length clinical chronic disease management. The one thing to remember is that chronic disease management must have efficacy in achieving its aims, but also must not have side effects. When these two prerequisites are in place, the patients are willing to cooperate with the treatment, with high compliance. The better the effect the higher the compliance rate. These two aims support each other. The key point in this process is the need to find a cure that has no side effects. In this regard, exercise is a very good method, but to make already hardened blood vessels elastic again using exercise alone may take a very long time. If you can use the human regeneration mechanism to find the key to open this mechanism, so that the body can regenerate its own new endothelial cells, and use exercise, the end result of restoration of vascular elasticity will be achieved more readily.

 

In order to explore the mechanism of human body's own regeneration, we have done more clinical trials. For example, we launched a ten-year plan with Harvard University, the world's top institution, and observed and tracked relevant patients. Preliminary results showed that angiogenesis of nerve repair was most effective in treating insomnia. And the world's top hospital, the Mayo Clinic, carried out a double-blind clinical trial, the results of which will be released at the end of the year. The top three hospitals in Shanghai also launched a double-blind clinical trial. After four years of hard work, they have passed factory verification, quality verification, etc. Finally, they obtained the market access certificate issued by the Shanghai Food and Drug Administration in 2014, becoming a standard medical device product.

 

At present, the E.U. also gives the R7 technology CE certificate, and the U.S. FDA confirms the safety of R7 products allowing hospitals and even the general public to apply for the device. This is a new field and a new direction carrying out the regeneration of human body on the basis of sports.

 

 

 

Outpatient magazine

R7 is a new technology. What expectations do you have for this new technology?

 

Jack Wang

 

R7 is the use of pulsed electromagnetic field (PEMF) from the perspective of the disease mechanism, targeting microcirculation and noninvasive vascular revascularization technology to achieve normalization. Its non-toxic side effects and convenient mobility has been demonstrated in more than 30,000 cases. Data has been gathered proving that 20 different kinds of chronic diseases have been treated successfully with improvement, such as the effective rate of improved sleep reaching 80% or more, due to the improvement of microcirculation. Microcirculation seems to be a precise target treatment of chronic diseases. The emergence of this technology has added a new choice for the field of mobile medical treatment and the prevention and rehabilitation of cardiovascular and cerebrovascular diseases. If double-blind clinical trials in animal and human experiments continue to prove its usefulness, the R7 may be like a portable application, becoming a therapeutic tool for everyone.

 

 

 

Outpatient magazine

As an expert in the field of chronic disease control, please share your experience in clinical practice of chronic disease management and your personal experience in the application of R7. And your expectations for future chronic disease control?

 

Professor Hu

 

Prevention of cardiovascular disease is very important, but at present, many in our country are "sitting doctors," waiting for sick patients to seek medical treatment. The patients themselves do not pay attention to recovery and prevention, and over time, are caught in the cycle of "physician sit, patients sick" recurrence. In my opinion, patients should pay more attention to the prevention and rehabilitation of cardiovascular disease. To that end I created the 4s "Heart Health Club" across the country to provide members with Unexpected Emergency (Emergency Services)--Preventive Maintenance of the Heart (Screening and Treatment)—Tailored Cardiac Rehabilitation (Specialized Rehabilitation)—the Regular Maintenance of the Heart (Regular Follow-up Support) of “4s Service.”

 

The medical “4S shop” is a new type of medical service mode, but also a new type of cooperation mode, the core of which is to provide patients with disease counseling, health education, disease treatment, health management services, integrated and comprehensive cardiovascular health services throughout. For patients with cardiovascular disease, hypertension, diabetes and so on, the treatment technique is not limited to the biological treatment or surgery, but will make use of lifestyle prescriptions (including exercise prescriptions, nutritional prescriptions, psychological prescriptions, sleep prescriptions and drug prescriptions) in the form of interventions.

 

The application of new R7 technology can be seen intuitively--the regeneration of capillaries, red blood cells no longer aggregating and the reduction of white floccus. The visible effects can improve patient compliance. However, any innovation needs to be enriched and developed in practice. For R7, it is very important to prove its effectiveness and security through more data.

 

 

 

doctor profile

 

 

Hu Dayi
Peking University People's Hospital, Beijing United Family Hospital
Professor, Chief Physician, Doctoral Supervisor

Current Academician of the International Academy of Eurasian Sciences; Director of the World Heart Federation; Chairman of the International Society for Cardiovascular Pharmacology; Chairman of the China Heart Federation; Director of the American College of Cardiology (ACC) International; President of China Tobacco Control Association; Vice-chairman of China Preventive Medicine Association; Director of Professional Committee of the China Rehabilitation Medicine Cardiovascular Disease; Director of the Institute, Peking University People's Hospital; Vice President of the Chinese Society of Gerontology Council; Vice Chairman of the Chinese Society of Gerontology and Geriatric Medicine and Cardio-cerebrovascular Disease; Director of Professional Committee Member; Chief Editor of the Journal Hypertension Magazine.

 

 

Jack Wang
Biomobie (Shanghai) Regenerative Medicine Technology Co. LTD
CEO

The global CEO and inventor of Biomobie Regenerative Medicine Group; 25 years of entrepreneurship, inventing, and angel investment experience in Silicon Valley; successfully introduced patents in medical, electronic and mechanical fields to the mass consumer market. After 15 years of leading dozens of international cross-industry teams in China has successfully built ten, billion-level industrial projects.

Biomobie Corp., USA
Biomobie (Shanghai) Regenerative Medicine co., Ltd.
 

Scan qr code to share to WeChat